Clinical Trial Update: A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SAGE-718 for cognitive function in Huntington's disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Huntington's Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-09-05